Helena Granstam Björneklett

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A randomised controlled trial of support group intervention after breast cancer treatment: Results on anxiety and depression

Helena Granstam Björneklett, C. Lindemalm, Andreas Rosenblad et al. · Acta Oncologica · 2011 · 52 citations · Full text

Medicine, Oncology, Breast Oncology +16

Long-term follow-up of a randomized study of support group intervention in women with primary breast cancer

Helena Granstam Björneklett, Andreas Rosenblad, C. Lindemalm et al. · Journal of Psychosomatic Research · 2012 · 43 citations

Medicine, Oncology, Breast Oncology +7

A randomized controlled trial of a support group intervention on the quality of life and fatigue in women after primary treatment for early breast cancer

Helena Granstam Björneklett, C. Lindemalm, Marja-Leena Ojutkangas et al. · Supportive Care in Cancer · 2012 · 40 citations

Medicine, Oncology, Breast Oncology +11